17.50
0.92 (5.55%)
| Penutupan Terdahulu | 16.58 |
| Buka | 16.51 |
| Jumlah Dagangan | 1,369,683 |
| Purata Dagangan (3B) | 2,902,513 |
| Modal Pasaran | 2,881,414,144 |
| Harga / Buku (P/B) | 4.23 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Nov 2025 |
| EPS Cair (TTM) | -3.61 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 3.49% |
| Nisbah Semasa (MRQ) | 20.35 |
| Aliran Tunai Operasi (OCF TTM) | -319.72 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -176.84 M |
| Pulangan Atas Aset (ROA TTM) | -39.92% |
| Pulangan Atas Ekuiti (ROE TTM) | -64.01% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Dyne Therapeutics, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -1.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | -0.50 |
|
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 0.56% |
| % Dimiliki oleh Institusi | 110.24% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Atlas Venture Life Science Advisors, Llc | 30 Sep 2025 | 9,130,465 |
| Fcpm Iii Services B.V. | 30 Sep 2025 | 5,462,846 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 60.00 (HC Wainwright & Co., 242.86%) | Beli |
| Median | 38.50 (120.00%) | |
| Rendah | 16.00 (JP Morgan, -8.57%) | Pegang |
| Purata | 38.63 (120.74%) | |
| Jumlah | 7 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 19.07 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| JP Morgan | 20 Jan 2026 | 16.00 (-8.57%) | Pegang | 16.58 |
| 14 Nov 2025 | 17.00 (-2.86%) | Pegang | 18.79 | |
| Evercore ISI Group | 15 Dec 2025 | 36.00 (105.71%) | Beli | 19.59 |
| Stifel | 11 Dec 2025 | 39.00 (122.86%) | Beli | 19.42 |
| Oppenheimer | 10 Dec 2025 | 40.00 (128.57%) | Beli | 19.69 |
| 12 Nov 2025 | 11.00 (-37.14%) | Pegang | 18.61 | |
| Chardan Capital | 09 Dec 2025 | 38.00 (117.14%) | Beli | 18.44 |
| Morgan Stanley | 09 Dec 2025 | 50.00 (185.71%) | Beli | 18.44 |
| HC Wainwright & Co. | 08 Dec 2025 | 60.00 (242.86%) | Beli | 22.20 |
| 06 Nov 2025 | 46.00 (162.86%) | Beli | 18.21 | |
| RBC Capital | 06 Nov 2025 | 30.00 (71.43%) | Beli | 18.21 |
| Papar semua | ||||
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |